• In early August 2026, agilon health, inc. reported that second-quarter revenue rose to US$1,494.74 million from US$1,394.98 million a year earlier, with net income improving to US$17.96 million from a net loss of US$104.37 million and earnings per share turning positive.
• Alongside this return to profitability, the company raised its full-year 2026 total revenue outlook to a range of US$5.78 billion to US$5.86 billion and issued new third-quarter guidance, signaling greater confidence in its near-term operating performance.
• With agilon health back in the black and lifting full-year revenue guidance, we’ll examine how this reshapes its margin-focused investment narrative.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

agilon health Investment Narrative Recap

To own agilon health, you need to believe its value based care model for seniors can convert demographic tailwinds into durable margins, not just top line growth. The return to quarterly profitability and raised 2026 revenue outlook support that margin focused thesis, but they do not erase near term risks around payer negotiations and medical cost trends, which remain the most important catalyst and the biggest operational risk in the story right now.

The most relevant update here is the higher full year 2026 revenue guidance to US$5,775 million to US$5,860 million. This incrementally supports the idea that recent contract terms and cost controls are holding up better than feared, at least in the near term. For investors focused on whether agilon can stabilize margins after prior volatility in medical costs and risk adjustment revenue, this refreshed outlook is a key data point to watch against upcoming negotiation cycles.

Yet against this improving headline, investors should still be aware of how quickly payer negotiations or inpatient and oncology drug costs could...

agilon health's narrative projects $7.0 billion revenue and $45.0 million earnings by 2029.

Uncover how agilon health's forecasts yield a $78.14 fair value, a 28% downside to its current price.

Exploring Other Perspectives

Before this result, the most pessimistic analysts assumed only about 2.1 percent annual revenue growth and no profitability by 2029, so today’s profit and guidance lift could challenge that view and remind you that reasonable people can read the same numbers very differently.

Explore 4 other fair value estimates on agilon health - why the stock might be worth 28% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your agilon health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free agilon health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate agilon health's overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.